Clopidogrel Use in Elderly Patients with Acute Coronary Syndrome

Recommendations for Clopidogrel in Elderly ACS Patients

• The American Heart Association notes that there is little evidence on the use of a loading dose of clopidogrel in patients aged 75 years or older with NSTEMI and STEMI, and recommends caution in this population 1, 3
• For patients older than 75 years with ACS, there is insufficient evidence supporting the use of a loading dose of clopidogrel, as these patients were excluded from major studies on STEMI treated by fibrinolysis 1, 2

Age-Related Considerations for Antiplatelet Therapy

• Risk factors associated with higher bleeding rates with antiplatelet therapy include age ≥75 years, previous stroke/TIA, and body weight less than 60 kg 1, 3

Practical Approach for Elderly ACS Patients

• For elderly patients (>75 years) with ACS, the choice of antiplatelet therapy should be guided by local interdisciplinary review of ongoing clinical trials, guidelines, and recommendations 1, 3

Special Considerations and Caveats

• Prasugrel should be avoided in patients >75 years due to increased bleeding risk without mortality benefit compared to clopidogrel 1
• For elderly patients who may need urgent CABG, clopidogrel should ideally be discontinued 5-7 days before surgery 1, 4

Common Pitfalls to Avoid

• Automatically applying standard adult loading doses (300-600 mg) to elderly patients without considering age-related bleeding risk 1, 3
• Failing to recognize that elderly patients were excluded from many pivotal trials that established loading dose protocols 1, 2